Although it is well known that SGLT2 inhibitors induce ketogenesis in patients with type 2 diabetes, ketogenesis is not dominant in nondiabetic conditions and may not play an important role in nondiabetic heart failure35. Here, SLC5A2 is linked to type 2 diabetes mellitus.